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Abstract
The clinical utility of next-generation sequencing (NGS) for a diverse range of targets is expanding, increasing the
need for multiplexed analysis of both DNA and RNA. However, translation into daily use requires a rigorous and
comprehensive validation strategy. The aim of this clinical validation was to assess the performance of the Ion Torrent
Personal Genome Machine (IonPGM™) and validate the Oncomine™ Focus DNA and RNA Fusion panels for clinical
application in solid tumour testing of formalin-fixed, paraffin-embedded (FFPE) tissue. Using a mixture of routine
FFPE and reference material across a variety of tissue and specimen types, we sequenced 86 and 31 samples on the
Oncomine™ Focus DNA and RNA Fusion assays, respectively. This validation considered a number of parameters
including the clinical robustness of the bioinformatics pipeline for variant detection and interpretation. The
Oncomine™ Focus DNA assay had a sample and variant-based sensitivity of 99.1 and 97.1%, respectively, and an
assay specificity of 100%. The Oncomine™ Focus Fusion panel had a good sensitivity and specificity based upon the
samples assessed, however requires further validation to confirm findings due to limited sample numbers. We observed
a good sequencing performance based upon amplicon, gene (hotspot variants within gene) and sample specific
analysis with 92% of clinical samples obtaining an average amplicon coverage above 500X. Detection of some indels
was challenging for the routine IonReporter™ workflow; however, the addition of NextGENe® software improved
indel identification demonstrating the importance of both bench and bioinformatic validation. With an increasing
number of clinically actionable targets requiring a variety of methodologies, NGS provides a cost-effective and
time-saving methodology to assess multiple targets across different modalities. We suggest the use of multiple analysis
software to ensure identification of clinically applicable variants.
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Introduction
Personalised medicine for the treatment of cancer provides
directed therapy for patients based upon the genetic and epi-
genetic alterations of their disease. This requires laboratories
to provide rapid assessment of the molecular landscape of the
tumour to enable informed treatment decisions. Many of the
current clinical testing algorithms are laborious, with multiple
tests performed separately for a single patient. Next-
generation sequencing (NGS) enables the testing of multiple
genes, frommultiple patient samples across dual modalities in
one assay. The Ion Torrent NGS system is compatible with
FFPE tissue which is currently routine processing of patholo-
gy specimens [1] and requires minimal nucleic acid input
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(10 ng total of DNA or RNA) which is beneficial for testing
frequently very small, diagnostic samples.
With increasing affordability enabling the implementation
of NGS into clinical laboratories, validation of both assay and
bioinformatic analytical pipelines are the primary challenges
clinical laboratories face. To comply with ISO15189 accredi-
tation [2], validation of the detection of somatic variants must,
as a minimum, assess limit of detection, analytical sensitivity
and specificity, repeatability and reproducibility and set appro-
priate thresholds and quality control parameters for reliable
analysis of clinical specimens. Validation must also include
the handling of large amounts of data produced by multi-gene
panels [3].
This study presents the validation of the Oncomine™ Focus
DNA and RNA panel on the Ion Torrent Personal Genome
Machine (IonPGM™, Thermo Fisher Scientific) for joint im-
plementation within the Department of Molecular Pathology
and United Kingdom National External Quality Assessment
Service (UK NEQAS) for Molecular Genetics, Royal
Infirmary of Edinburgh, UK. The Oncomine™ Focus DNA
and RNA assay comprises two separate panels (DNA and
RNA) which were designed to interrogate hotspot mutations
(35 genes), copy number variations (19 genes) and gene fu-
sions in 23 genes. Combined, these two panels can identify
current actionable genetic variants and potential future targets
for personalised therapy.
Materials and methods
Sample selection
Seventy-eight anonymised FFPE tissues comprising of mela-
noma (n = 18), colorectal cancer (CRC) (n = 28), non-small-
cell lung cancer (NSCLC) (n = 22) and gastrointestinal stro-
mal tumours (GIST) (n = 10) were processed from a range of
specimen types: resections (n = 57), biopsies (n = 13), cell
blocks (n = 6), fine needle aspirate (FNA) (n = 1) and polyps
(n = 1). Neoplastic content was assessed and ranged from 20
to 90% as determined by a pathologist. In addition, nine ref-
erence samples were tested including four commercially avail-
able standards AcroMetrix™ Oncology Hotspot Control cata-
log no. 969056, AcroMetrix™ Frequency Ladder (six variant
allele frequencies: 2.8, 5.4, 11, 18.4, 29.5 and 47.9%),
Horizon Structural Multiplex Reference Standard catalog no.
HD753 and Horizon EGFR Gene-Specific Multiplex
Reference Standard catalog no. HD300 and six in-house ref-
erence standards: REF 2 (68 variants), REF 3 (6 variants),
REF 4 (133 variants), REF 5 (131 variants), REF 6 (9 vari-
ants) and REF 7 (9 variants) (S1 file). The limit of detection
was calculated using data from the AcroMetrix™ Hotspot
Frequency Ladder. RNA assay specificity and sensitivity
was assessed using clinical samples, four in-house reference
standards and the ALK-RET-ROS1 Fusion FFPE RNA
Reference standard (Horizon Diagnostics catalog no.
HD784, RNA REF 1–4). The Human Brain Total RNA
(Thermo Fisher Scientific, catalog no. AM7962) was used to
assess RNA reproducibility.
Nucleic acid extraction and quantification
DNAwas extracted from melanoma, CRC and GIST samples
using QIAmp DNA FFPE Tissue Kit (Qiagen) following
manufacturer’s protocol (excluding de-paraffinisation). Dual
DNA and RNA isolation was performed from NSCLC tissues
using the RecoverAll Total Nucleic Acid Isolation Kit for
FFPE (Thermo Fisher Scientific). DNA and RNA concentra-
tions were determined by fluorometric quantitation using
Qubit 2.0 Fluorimeter with Qubit DNA dsDNA BR Assay
Kit and Qubit RNA BR Assay Kit (Qiagen) as appropriate.
Next-generation sequencing
Complementary DNA (cDNA) synthesis prior to library prep-
aration for RNA panel was carried out using SuperScript™
VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific,
11754050). Library preparation was carried out using the
Oncomine Assay™ (comprising the DNA Oncomine™
Focus Assay (Thermo Fisher Scientific) and RNA
Oncomine™ Fusions assay (Thermo Fisher Scientific)) fol-
lowing manufacturer’s instructions using a total of 10 ng input
DNA and or RNA per sample (minimum 0.83 ng/μl sample
DNA concentration). A maximum of seven DNA samples
were prepared per run (six samples if both DNA and RNA
analyses were required) on an Ion 318™ v2 chip (Thermo
Fisher Scientific, catalog no. 4488150). The DNA panel can
identify hotspot mutations in the following genes: AKT1,
ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2,
ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ,
HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS,
MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA,
PIK3CA, RAF1, RET, ROS1 and SMO; however, not all genes
were assessed for the purposes of this validation. The RNA
panel can identify rearrangements in ALK, RET, ROS1,
NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, MET,
BRAF, RAF1, ERG, ETV1, ETV4, ETV5, ABL1, AKT3, AXL,
EGFR, ERBB2, PDGFRA and PPARG, not all fusions were
assessed for this validation. Nineteen copy number variant
(CNV) targets are also included in the Oncomine™ Focus
Panel; however, these were not validated in this study.
Template preparation was performed on the Ion Chef
System (Thermo Fisher Scientific) using the Ion PGM Hi-Q
Chef Kit and/or the Ion One Touch™ 2 System using the Ion
PGM Template OT2 200 Kit. Sequencing was performed
using the Ion PGM Hi-Q Sequencing Kit on the Ion Torrent
Personal Genome Machine (Ion PGM).
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Data analysis
Analysis was carried out using Ion Torrent Suite™ Browser ver-
sion 5.0 and Ion Reporter™ version 5.0. The Torrent Suite™
Browserwas used to perform initial quality control including chip
loading density,median read length and number ofmapped reads.
The Coverage Analysis plugin was applied to all data and used to
assess amplicon coverage for regions of interest. Variants were
identified by Ion Reporter filter chain 5% Oncomine™ Variants
(5.0).A cut off of 500X coverage was applied to all analyses. All
identified variants were checked for correct nomenclature using
Alamut Visual v.2.7.1 (Interactive Biosoftware). Any discrepan-
cies in variant identification, between Ion Reporter and Alamut,
were validated manually using the Integrative Genomics Viewer
[4, 5] and NextGENe® v2.4.2 (SoftGenetics®). For the purposes
of this validation, amplicons covering clinically actionable re-
gions with known mutation status (termed target amplicons;
Table 1) were assessed as a subset of all amplicons (amplicons
which target hot spot variants, i.e. SNVs and indels) covered in
the Oncomine™ Focus hot spot BED file.
Results
Oncomine™ focus DNA panel
Sequencing performance
Of the 78 FFPE samples, for 4 samples (exclusively NSCLC),
no amplicons were covered to 500X (minimum criteria for this
validation) and were considered failed samples. All failed
samples had an input DNA concentration below 2.34 ng/μl;
however, not all samples below this DNA input failed se-
quencing. No relationship between DNA concentration and
amplicon coverage was identified.
The overall panel performance was assessed by average
amplicon (n110) coverage across all cases (n78). The majority
(99%) of all amplicons were covered on average to a minimum
of 500X. The PIK3CA amplicon, CHP2_PIK3CA_6, which
covers nucleotides in the later portion of exon 8 was the only
ampliconwith an average coverage below 500X across all cases
(Fig. 1a). A high variability in amplicon coverage within and
between gene variants (n35) was observed across the combined
study cohort. For example, intra-gene variation in EGFR
amplicon coverage across eight amplicons ranged from
Median (Md) 686–4853, inter-gene variation in PIK3CA exon
8 (Md 327) and KIT exon 11 (Md 4008) (Fig. 1b). A trend was
observed between median amplicon coverage and amplicon
length (Spearman’s rho; p = 0.072) and betweenmean amplicon
length and amplicon GC content (Spearman’s rho; p = 0.071).
The average amplicon coverage per samplewas also assessed;
89.7% (70/78) of all samples had an average amplicon coverage
above 500X. A large proportion of samples (62/78, 79.4%) had
an average amplicon coverage for the Oncomine Focus assay
between 500 and 3000X (Fig. 2). No significant association be-
tween DNA concentration, sample type or tissue type could be
identified in the seven samples exceeding an average amplicon
coverage of 3000X.
Sample performance using the Focus panel was assessed
based upon the proportion of amplicons reaching a minimum
of 500X coverage for all amplicons and target amplicons, re-
spectively. All amplicons were covered to a minimum of 500X
in 12.8% of samples, and all had an input DNA concentration
above the recommended 10-ng total input (range 1.97–
125.5 ng/μl). Sixty-four samples (82%) had a proportion of
amplicons covered to a minimum of ×500 (range 4.5–99.1%,
Md 90%). Of the target amplicons (Table 1), 19 (24.4%) sam-
ples had all target amplicons covered to a minimum of 500X, all
cases of which had an input DNA concentration above the
recommended 10-ng input (range 1.29–125 ng/μl). Seventy
four (94.9%) had a proportion of target amplicons covered to
Table 1 Target amplicons
Number of amplicons Gene Tissue type
8 EGFR
Lung
3 KRAS
CRC
10 PIK3CA
3 NRAS
Melanoma2 BRAF
5 KIT
GIST
3 PDGFRA
Table details ‘target amplicons’ per tissue type and number of amplicons covering each gene of interest based upon current clinical and EQA
requirements within UKNEQAS and Molecular Pathology at the Royal Infirmary of Edinburgh
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Fig. 1 Assessment of amplicon- and gene-based sequencing performance
by average amplicon coverage. a Average amplicon coverage across all
clinical samples tested (n78). Ninety-nine percent of amplicons were
covered on average to a minimum of 500X 1Average amplicon coverage
was assessed for all hotspot amplicons in the Oncomine™ Focus assay. b
Median amplicon coverage across all genes. Median coverage per gene
(n35) comprising of a number of hotspot variants across exons per gene.
A high variability in amplicon coverage was observed within and be-
tween genes. Intra-gene variability is depicted by interquartile range
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Fig. 2 Sample-based sequencing performance. Sample-based sequencing
performance was assessed by the average amplicon coverage (all hotspot
amplicons) for all genes (n35) for each sample. A large proportion of
samples had an average amplicon coverage for all genes between 500
and 3000X. Seven samples exceeded 3000X coverage with a maximum
6707X coverage. Eight samples had average amplicon coverage below
500X with two samples failing to sequence any genes
Table 2 Sequencing performance
metrics Total mapped
reads (CV)
Average amplicon
coverage depth (CV)
Percent of all
amplicons ≥ ×500
Percent of target
amplicons ≥ ×500
Total (n78)
Tissue type
Lung (n22) 390,884 (0.89) 1,545 (0.83) 61 64.3
GIST (n10) 507,137 (0.35) 1,861 (0.35) 81 88.8
Melanoma (n18) 396,993 (0.32) 1,447 (0.33) 82.6 85.6
CRC (n28) 441,153 (0.72) 1,613 (0.73) 73.7 81.7
p value 0.120 0.175 0.186 0.033a
Specimen type
Cell block (n6) 469,270 (1.06) 2,166 (0.8) 61.2 62.8
Biopsy (n13) 374,194 (0.79) 1,371 (0.8) 59 69.2
Resection (n57) 430,195 (0.59) 1,569 (0.59) 77.3 81.9
p value 0.840 0.613 0.664 0.692
Sequencing performance metrics (total mapped reads, average amplicon coverage, percentage of all amplicons ≥
500X, percentage of target amplicons ≥ 500X). Metrics are presented by tissue type and specimen type. Mean
values are reported. A significant difference in % target amplicons at 500X between tissue type was identified;
however, adjustment for false discovery rate (FDR) using Bonferoni correction deemed this not significant
(Kruskal-Wallis p = 0.033; n78). There was however a trend in NSCLC samples having a lower percentage of
amplicons at ≥ 500X than the other tissue types
a p value significant at 0.05. For specimen type analysis 2 samples, one fine needle aspirate and one polyp were
excluded from statistical analysis due to limited numbers of samples of this type. Coefficient of variation stated for
total mapped reads and average amplicon coverage
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a minimum of 500X (range 2.9–97.1%, Md 88.2%). Based
upon mean sequencing performance metrics, there was no sig-
nificant difference in average amplicon coverage, total mapped
reads or percentage of amplicons at 500X between samples
based upon tissue type or sample type (Table 2).
Tissue-specific sequencing performance was assessed by the
percentage of target amplicons (specific to tissue type; Table 1)
with minimum 500X depth of coverage per sample; 35 samples
(44.8%) had all target amplicons covered to minimum 500X.
GIST and melanoma samples had a greater proportion of sam-
ples achieving minimum 500X for all target amplicons (80 and
61.1%, respectively). Melanoma and GIST had the highest av-
erage percentage of tissue-specific target amplicons at 500X
(per sample) (91.3 and 90.3%, respectively) whilst CRC and
NSCLC had 78.8 and 68.4%, respectively.
Limits of detection
The limit of detection (LOD) were ascertained by repeated
sequencing of the AcroMetrix™ Frequency Ladder which
was analysed at the three lowest expected allele frequencies
(EAFs) (2.8, 5.4 and 11%) for the presence of variants across
all three repeats (S2 file).
Of the target genes assessed (Table 1), all (7) EGFR exon 21
variants failed to be detected at any of the three frequencies.
These variants were reliably identified at 18.4% EAF; however,
the observed variant allele frequency (VAF) was much lower
than expected (average observed VAF 6.6%). Due to the perti-
nence of EGFR mutations in NSCLC, this was deemed an un-
satisfactory LOD and required further investigation. Using the
Horizon Discovery EGFR Gene specific multiplex reference
standard (HD300) containing exon 21 variants, c.2582 T >A
and c.2573 T >G at an EAF of 5%, all five variants (in addition
to those above, c.2369C>T, c.2236_2250del and c.2155G>A)
were detected at VAF between 4.5 and 6.2%, confirming a min-
imum LOD of 5% for the EGFR gene for these variants. LODs
for BRAF, EGFR, KRAS and NRAS were 5.6% across all exons
assessed and 11% for PDGFRAwhilstKITand PIK3CA demon-
strated varying LODs depending upon exon assessed (Table 3).
Of the variants assessable in the AcroMetrix™ Frequency
Ladder, all variants in only one gene (GNA11) could be detected
at the 2.8% EAF for all variants. Ten genes (40% of total genes
identified) had all variants detected across triplicates at 5.4% EAF
(ALK, BRAF, CTNNB1, EGFR, FGFR1, FGFR2, IDH1, KRAS,
MET, NRAS and SMO). In addition to these, a further eight genes
(76% of total genes identified) had all variants detected across all
three runs at 11% EAF (AKT1, ERBB2, GNA11, HRAS, IDH2,
JAK2,MAP2K1 and PDGFRA). LODs for all genes included in
the AcroMetrix™ Frequency Ladder are detailed in S2 file.
In addition, during LOD analysis, we identified observed alle-
lic frequencies with an element of positive or negative bias across
repeats; e.g. observed VAFs were consistently higher than
expected in some genes (BRAF, EGFR, KRAS, NRAS and
PIK3CA) and consistently lower than expected in others (KIT
and PDGFRA).
Robustness
Library preparations and sequencing runs were performed four
times using theAcroMetrix™OncologyHotspot Control, which
contained 146 targeted variants across 25 genes (S3 table), to
determine assay inter-run reproducibility. One-hundred and
forty-three variants were detected across all runs.
Using Ion Reporter™ (IR™) routine workflow, three false neg-
atives were identified (FGFR3 c.1928A > G, PDGFRA
c.1698_1712del15 and IDH2 c.474A>G) being absent from 2,
2 and 1 repeat, respectively. Conferring a routine workflow repro-
ducibility for the variants assessed of 97.9%. The FASTQ files
from the four repeats were further analysed by NextGENe® soft-
ware (SoftGenetics®). Using this analysis, the variants that com-
prised the initial three false negatives from the IR routineworkflow
were identified in all four repeats; however, three different false
negatives were produced using this analysis (MET c.3757 T>G,
MET c.3778G>T and RET c.1894_1906 >AGCT) being absent
from 1, 1 and 4 repeats, respectively (S3 file).
Intra-run repeatability was assessed by duplicate analysis
of the 5.4% EAF (11/25) and 11% EAF (20/25) Acro-Metrix
Hotspot Frequency Ladder samples containing 25 genes
(hotspot variants within gene) comprising 140 variants; 44%
(mean VAF 6.9%, CV 0.22) and 80% (mean VAF 11%, CV
0.22) repeatability was observed for all genes (hot spot vari-
ants within gene) at EAF levels 5.4 and 11%. On a variant
basis for duplicate analysis of the 5.4 and 11% EAF, a repeat-
ability of 96/140 (68.5%, mean VAF 6.6%, CV 0.22) and 132/
140 (94.2%, mean VAF 10.6%, CV 0.23), respectively, was
identified (S4 file).
For some variants, there was a large difference between the
expected and observed VAFs demonstrating a positive or neg-
ative bias, thus preventing accurate VAFs to be derived. This
was observed at both inter- and intra-gene level (Figs. 3 and 4).
Analytical sensitivity and specificity
Sensitivity assessment of theOncomine™FocusDNAPanelwas
determined at both variant (reference samples and clinical mate-
rial) and sample level (clinical material only). For the purposes of
sensitivity analysis, only pre-validated variants were assessed.
Any additional identified variants not previously validated were
not included in analysis. A total of 588 variants (across 86 sam-
ples) were sequenced, 6 of these failed due to quality and were
removed from further analysis. At the variant level, 571 of 576
known variants were correctly identified conferring an analytical
variant-based sensitivity of 99.13% (95%CI 99.1–99.15%). Five
false negative results were identified (Table 4).
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Table 3 Limits of detection determination for target genes
Gene Mutation CDS
Exo
n
Bia
s
Expected allele frequ
ency LOD (average percent of allele freque
ncy)*
2.75 5.4 11
BRAF
c.1799 T > A
15 1.4
5.4 (4.3–6.5)
c.1790 T > G
c.1781A > G
c.1742A > G
c.1391G > T
11 1.7c.1380A > G
c.1359 T > C
EGFR
c.323G > A
3 1.3
5.4 (5–5.8)
c.340G > A
c.866C> T
7 2.7
c.874G > T
c.1793G > T 15 2.4
c.2092G > A
18 5.4c.2156G > C
c.2170G > A
c.2197C> T
19 2.9
c.2203G > A
c.2222C> T
c.2235_2249del15
c.2293G > A
20 3
c.2375 T > C
c.2485G > A
21
a
0.3 5
c.2497 T > G
c.2504A > T
c.2515G > A
c.2573 T > G
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Table 3 (continured)
c.2582 T > A
c.2588G > A
KIT
c.1509_1510insGCC
TAT
9 −0.4
5.4 (5.3–5.5)
c.1516 T > C
c.1526A > T
c.1535A > G
c.1588G > A 10 0.2
c.1698C> T
1 −1.9 11 (10.5–11.5)c.1727 T > C
c.1755C> T
c.1924A > G
13 −0.7 5.4 (5.2–5.6)
c.1961 T > C
c.2410C> T 17 −2.2 11 (10.9–11.1)
KRAS
c.351A > C 4 0.7
5.4 (5.3–5.5)
c.183A > C
3 0.5
c.175G > A
c.111 + 1C> T
c.104C> T
c.35G > A
c.24A > G
NRAS
c.182A > G
3 3.2
5.4 (4.7–6.1)
c.174A > G
c.52G > A
2 0.8c.35G > A
c.29G > A
PDGFRA
c.1743 T > C
14 −1.4
11 (10.9–11.1)
c.1977C> A
c.2001A > G
c.2517G > T
18 −1.6c.2525A > T
c.2544C> A
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At the sample level, 71 out of 74 samples were suc-
cessfully sequenced (69 gave concordant genotypes)
giving an analytical sensitivity of 97.1% (95% CI
97.06–97.3%).
Variant-based assay specificity was assessed on 157
alternate variant negative genes (hot spot regions previ-
ously assessed) and conferred a 100% sensitivity with
no false positives identified in hotspot regions assessed.
Analytical assay specificity was determined based on
the analysis of 77 FFPE samples; no false positives
were detected conferring 100% analytical specificity.
Overall, we identified a positive predictive value of
100% and a negative predictive value of 97.5%.
Bioinformatic performance
Of the false negatives identified in sensitivity analysis, sample
6 was previously validated using Sanger sequencing and
contained a KIT c.1652_1663del p.Pro551_Val555delinsLeu
mutation. This variant was absent in the initial output from Ion
Reporter™; adjustment of analysis parameters and re-analysis
resulted in successful identification of the variant, indicating
that this mutation had been successfully sequenced but filtered
out by the bioinformatics pipeline. The presence of the variant
was confirmed by analysis of the FASTQ file with
NextGENe® software (SoftGenetics®). Sample 71 that
contained a second kit mutation c.1676_1694delinsA
Table 3 (continured)
PIK3CA
8 2.1
c.1370A > G
c.1616C> G
10 1.5
5.4 (5.2–5.6)
c.1624G > A
c.1633G > A
c.1640A > G
c.2102A > C 14 1.2
c.2702G > T
19 0.6
c.2725 T > C
c.3110A > G
21 1.3
c.3140A > G
Limit of detection analysis for target genes. BRAF, KRAS and NRAS were successfully identified across three repeats
at 5.4% EAF. PDGFRA was identified across three repeats at 11% EAF. Varying exons of KIT and PIK3CA demonstra
ted different LODs within the same gene (5.4 and 11%). Bullet indicates variant detected at expected allele frequency.
All variants listed are included in the AcroMetrix Frequency Ladder
™
*95% confidence intervals at LOD stated
EGFR exon 21 variants (c.2582 T > A and c.2573 T > G, highlighted in dark grey) were assessed using Horizon Discov
ery EGFR gene-specific multiplex reference standard (HD300). Variants listed in EGFR exon 21 other than those asses
sed in the Horizon Discovery gene specific multiplex reference standard (highlighted in light grey) were successfully rep
eated across three repeats at 18% EAF
a
c.93A > G
2 1
5.4 (5.2–5.6)
c.180A > G
c.971C> T
5 0.8c.1002C> T
c.1035 T > A
c.1258 T > C
11 (9.5–12.5)
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p.(Val559_565delinsGlu) was not identified by either the orig-
inal Ion Reporter™ algorithm or the adapted pipeline. The pres-
ence of this variant was also identified by NextGENe® software
(SoftGenetics®).
Due to a number of clinical targets residing within
KIT and PDGFRA genes involving indels, we sequenced
a further five cases with known indels. Using the normal Ion
Reporter™ workflow for Oncomine DNA single sample analy-
sis, 1/5 (20%) variants were identified. One additional variant
was identified using a modified Ion Reporter™ workflow (soft-
clipping parameters were decreased to enable greater sensitivity
at ends of reads), three remained unidentified. The FASTQ files
from these samples were analysed via NextGENe® software
(SoftGenetics®), whereby 3/5 (60%) variants were successfully
identified (Table 5). No additional false positives were identified
using theseworkflows. Basic detection parameters, i.e. minimum
SNV coverage and SNVallele frequency, were comparable be-
tween the two analysis software. No single workflow successful-
ly identified all five variants.
Six variants were identified with incorrect nomenclature by
the Ion Report algorithm 5.0. Validation and correction of
these calls was carried out using NextGENe® v2.4.2
(SoftGenetics®) and Alamut Visual v.2.7.1 (Interactive
Biosoftware). A large proportion of nomenclature
inconsistences were limited to deletions, insertions and dupli-
cations (Table 6).
Oncomine™ RNA fusion panel
Thirty-one FFPE samples (6 biopsies, 8 cell blocks, 9 resections
and 8 reference samples) previously validated by FISH were
tested using theOncomine™ Focus RNA fusions panel. A higher
sequencing failure rate was observed with the RNA panel than
the DNA; eight (25.8%) cases failed sequencing. These failures
were not associated with age of sample. All failed samples had a
DNA concentration below 8 ng/μl; however, not all samples
below this concentration failed fusion analysis. Of the 23 samples
which passed quality control, all fusion positive cases (n = 6)
were correctly identified conferring an assay sensitivity of
100%. At the fusion level, all 31 fusions were identified across
23 samples conferring 100% specificity. One sample was identi-
fied as having an additional variant MET(8)–MET(9), which
would not have been identified by current testing methodologies
as this is not part of current clinical testing algorithms. Intra- and
inter-run reproducibility was assessed using an EML4(6)–
ALK(10) positive sample and demonstrated 100% concordance
between and within runs. In addition, repeated analysis of the
Fig. 3 Inter-gene variation in expected allele frequency (EAF). Average
variant allele frequency for 25 genes represented in the AcroMetrix™
hotspot frequency ladder. Standard deviation of represented variants
within each gene is depicted. 1 NRAS, 2 ALK, 3 IDH1, 4 CTNNB1, 5
PIK3CA, 6 FGFR3, 7 PDGFRA, 8 KIT, 9 APC, 10 EGFR, 11 MET, 12
SMO, 13 BRAF, 14 FGFR1, 15 JAK2, 16 GNAQ, 17 RET, 18 FGFR2, 19
HRAS, 20 KRAS, 21 AKT1, 22MAP2K1, 23 IDH2, 24 ERBB2, 25GNA11.
Black triangle 2.8% EAF, cross 5.4% EAF, black circle 11% EAF
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FirstChoice Human Brain Reference Total RNA showed 100%
concordance between expression control presence, imbalance
assay and fusion assay calls. Further confirmation of validation
parameters is required prior to the clinical implementation of the
RNA Fusion assay.
Discussion
With an increasing requirement of clinical laboratories to perform
multiple gene testing in both DNA and RNA, NGS panels de-
signed for FFPEmaterial provide a solution.Many commercially
Fig. 4 Intra-gene variation in
expected allele frequency (EAF).
a NRAS variants at 2.8, 5.4 and
11% EAF. b EGFR variants at
2.8, 5.4 and 11% EAF excluding
exon 21 variants. A large variance
is observed within genes at the
2.8% EAF; this variance
decreases with increasing EAFs.
A large proportion of genes
demonstrate positive or negative
bias from the EAF. Variation
patterns observed between exons
of same gene
Table 4 False negative results for
variant and sample-based
sensitivity
False negatives Sample type Sample number Gene Expected variant
(genomic nomenclature)
Variant sensitivity Reference REF1 PDGFRA c.1698_1712del
Reference REF1 IDH2 c.474A>G
Reference REF 2 FGFR3 c.1928A >G
Variant and sample sensitivity Clinical 6 KIT c.1652_1663del
Clinical 71 KIT c.1676_1694delinsA
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available NGS panels include > 400 targets, making the task of
validating a solid tumour panel for implementation in a clinical
setting very challenging. In this study, we validated the
Oncomine™ Focus Panel for DNA and the Oncomine™ Fusion
panel for RNA application using a diverse cohort of validation
material consisting of both clinical and reference material en-
abling comprehensive validation of both sequencing platform
and bioinformatics performance.
We validated the assay on both wet bench and bioinformatics
processes across a broad spectrum of validation parameters in-
cluding sequencing performance, analytical sensitivity and spec-
ificity, reproducibility, repeatability, robustness and limit of de-
tection. A number of guidelines for the application of NGS se-
quencing and analysis clinical testing are available; however, a
general consensus as to validation size, its application in the
somatic setting and howparameters are assessed remains difficult
to elucidate [6, 7, 11]. This validation was conducted using sam-
ples representative of the clinical samples routinely processed on
site at the Royal Infirmary of Edinburgh including NSCLC,
CRC, Melanoma and GIST. The main aim of the validation
was to determine the overall applicability of the Ion PGM and
Oncomine™ Focus Panel for DNA and Oncomine™ Fusion
Panel for RNA to routine clinical testing. The appeal of the
Oncomine™ Focus panel for clinical application is the require-
ment of a small starting input of DNA, which is particularly
applicable when tissue availability is limited for example with
NSCLC specimens.
Overall, we observed good amplicon coverage and sequenc-
ing performance for the Focus panel; however, sub-optimal per-
formance for specific cases could not be associated with either
sample or tissue type and may be derived from pre-processing
procedures, prior to reaching the testing facility. Inadequate sam-
ple fixation and the type of fixative used have been shown to
have an impact on DNA/RNA quality and the performance of
downstream molecular procedures [12, 13]. For our FFPE sam-
ple cohort, we identified a clinically suitable analytical sample
sensitivity and specificity of 100%, which is comparable with
studies of similar panels and platforms [14, 15]. We did identify
differences in the performance of variant identification between
SNVs and indels, with the detection of indels presenting a greater
challenge for routine bioinformatic workflows in comparison to
SNVdetection; this has been previously identified in a number of
studies. In order to commence integration of NGS into routine
clinical testing algorithms, parallel testing using both single-gene
methods and NGS for prospective cases may be implemented to
further cement the findings from this initial validation.
The applicability of theOncomine™Focus panelwas easier to
assess due to the wide range of clinical material available for
validation. Two of the 78 samples assessed for this validation
were below the minimum input requirements for the assay of
which one sample failed to sequence any amplicons. The DNA
quantification kit used in this study is known to lack precision
below 5 ng/μl, which comprised 32 (41%) of the total samples
assessed by the DNA panel. For future assessment of DNA
Table 6 Nomenclature inconsistencies by Ion Reporter™
Gene Expected variant Ion Reporter™ variant
KIT c.1672_1674dupAAG p.(Lys558dup) c.1670_1671insGAA p.([Lys558dup)]
c.1679_1681delTTG p.(Val560del) c.1675_1677delGTT p.(Val559del)
c.1735_1737 p.(Asp579del) c.1733_1735delATG p.(Asp579del)
c.1730_1738del p.(Pro577_Asp579del) c.1728_1736del p.(Pro577_Asp579del)
EGFR c.2303_2311dup p.(Ser768_Asp770dup) c.2300_2301insCAGCGTGGA p.(Ala767_Ser768insSerValAsp)
BRAF c.1798_1799delGTinsAA p.(Val600Lys) c.1798_1799delGTinsAA p.(Val600Lys) plus c.1798G>A p.(Val600Met)
Five variants were identified by the IonReporter™ analysis workflow with the incorrect nomenclature and checked by Alamut Visual v2.7.1 (Interactive
Biosoftware). A large proportion of nomenclature errors were deletions, insertions and duplications
Table 5 Challenging variant
identification Gene Expected variant
(genomic nomenclature)
IR™ normal
workflow
IR™ deletion
workflow
NextGENe®
KIT c.1655_1660del ●
c.1728_1766dup
c.1726_1731dup ● ● ●
c.1656_1676del ●
PDGFRA c.2526_2537del ●
One of five variants was identified by IR™ routine workflow; an additional variant was identified by the IR™
deletion workflow. Three variants were identified by NextGENe® (SoftGenetics®) analysis, two of which had
not previously been identified by either IR™ workflows
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quantification, the Qubit dsDNA HS Kit (Thermo Fisher
Scientific), which has been shown to be sufficient in determining
sample DNA concentration for NGS, would be a more sensitive
method to better assess sequencing performance in relation to
DNA input [8, 16]. To explore the clinical impact minimum
DNA input requirements of the assay has on the number of cases
which would be applicable to this method, an audit was carried
out on 865 clinical samples for which DNA concentration had
been quantified previously prior to testing using current routine
methods. Ninety percent of caseswould be considered applicable
to sequencing by the Ion PGM platform with DNA concentra-
tions greater than the 10 ng total requirement of the assay. Of
those that would be below this threshold, 65% are derived from
NSCLC samples.
We successfully sequenced 94.8% of samples in our FFPE
validation cohort, which is comparable with other studies [10,
17]. A number of previous studies validating NGS platforms for
solid tumour application have used 500X coverage as a mini-
mum coverage criterion, which theoretically provides sufficient
coverage to detect a 2%MAF, although coverage below this can
be informative when variant alleles are at a higher frequency [3,
11, 18]. A broad range in average amplicon coverage was ob-
served at both the inter- and intra-gene level.We hypothesise that
amplicons with lower average amplicon coverage could be more
affected by amplification-associated issues such as comprising
highly repetitive sequences resulting in reduced PCR proficiency
and quality for subsequent sequencing [11].
Non-small-cell lung cancer comprises a large proportion of
the clinical workload within molecular pathology at the Royal
Infirmary of Edinburgh, with the requirement of the assessment
of multiple targets via a variety of methods supporting the appli-
cation of multi-gene panels on NGS systems. From this valida-
tion however, NSCLC would appear to be the most challenging
cases within the validation cohort with respect to meeting the
initial demands of DNA input through to sequencing perfor-
mance. Samples from this tissue type had the lowest percentage
of all amplicons and target amplicons covered to a minimum
coverage of 500X with the four samples failing to sequence
any amplicons being exclusive to NSCLC. Studies involving
assessment of NGS application forNSCLChave reported similar
findings [9]. Despite that coverage below 500X can be informa-
tive when variant alleles are at a higher frequency, the findings
from this validation demonstrate a higher degree of difficulty in
the identification of lower-frequency variants in those
amplicons which are below 500X coverage. For example
using a minimum variant coverage of 10X in order for a var-
iant call to be made by IonReporter™, coverage of 200X
would be sufficient (assuming good quality reads) of detecting
an alternate variant at approximately 5% frequency. The chal-
lenges presented by this sample group in terms of meeting
input requirements and deriving quality sequencing data put
pressure on meeting the clinical demands of returning timely
results if repeat testing is required due to failed samples.
Current methods for NSCLC testing (qPCR, pyrosequencing
and FISH) enable results to be published to clinicians from the
site of this validation within 5 days. To achieve a balance be-
tween cost per sample and time to results, turnaround times
would be required to be increased from 5 to a minimum of
10 days. In order to meet testing demands, urgent requests will
continue to be assessed using single-gene tests. Based upon the
reduced sequencing performance of NSCLC in this validation,
further validation to identify an accurate optimal threshold of
sample quality prior to input will be required in order to triage
samples more likely to fail and test these using single-gene test
methods. NSCLC samples showed a high failure rate when
assessed using the Fusions RNA panel which we hypothesise
may be attributed to a higher proportion of larger samples in
our validation cohort. In addition, this may also be as a result
of sample processing methods prior to molecular testing such as
length and extent of fixation of sample [19]. Obtaining clinically
relevant ALK-positive material for validation is challenging; for
example, out of 82NSCLC cases tested for ALK rearrangements
within Molecular Pathology in 2017, approximately 1% would
test positive for ALK rearrangements. In addition to this, ROS
testing is not currently carried out within Molecular Pathology
making the identification of ROS positive cases for validation
even more difficult. The limitations in the availability of clinical
FFPE material to validate the panel further demonstrate the chal-
lenges in validating the RNA fusions panels for clinical applica-
tion. In comparison to NGS fusion analysis, current methods for
detecting ALK rearrangements in NSCLC, i.e. fluorescent in situ
hybridisation (FISH), are relatively quick and cost-effective;
based upon this, the RNA Fusion panel is not currently
implementable as a clinical assay for assessment of ALK
rearrangements.
In addition to the issues identified with sequencing perfor-
mance of NSCLC specimens, we also identified issues in deter-
mining LODs for exon 21 of EGFR when using the
AcroMetrix™ Oncology Hotspot Control. This exon is pertinent
to NSCLC as it is required for the assessment of patient suitabil-
ity for treatment with tyrosine kinase inhibitors such as erlotinib
(Tarceva®). Detection of EGFR exon 21 variants using the
AcroMetrix™ Hotspot Frequency Ladder gave surprisingly high
LODs, comparable to those produced by Sanger sequencing. To
further explore the LODs of this exon using an additional refer-
ence standard, we confirmed that the clinically required variants
were detectable at 5%VAF. The challenges faced with ascertain-
ing LODs in this validation study highlight the importance of
using multiple types of reference material to gauge LODs on a
per exon basis.
The use of the AcroMetrix™ Hotspot Frequency Ladder en-
abled us to assess limits of detection across a broad range of
genes and variants in one sample which would otherwise be a
costly and time-consuming process. Our assessment of LODs
using this reference standard demonstrated inter- and intra-gene
variability from the EAFs. This highlights the unsuitability of this
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platform for the accurate reporting of VAFs and the importance
of validating LODs on a wide range of variants if clinical targets
span a number of amplicons as LODs may differ by exon [20,
21]. Variation in the observed VAF and EAF was identified,
which varied depending upon the gene and exon assessed. In
addition, during LOD analysis, we identified observed allelic
frequencies with an element of positive or negative bias across
repeats; e.g. observed VAFs were consistently higher than ex-
pected in some genes and consistently lower than expected in
others. We hypothesise that this could be caused by a number of
factors including library preparation and sequencing, location of
targets within the gene or the surrounding context of the content
to be sequence, i.e. large homopolymer regions. The quality of
DNA input into the assay may have a large impact on the allelic
frequencies observed following sequencing due to the nature of
AmpliSeq technology. We are unable to determine the extent of
duplicate reads in our final product prior to sequencing using our
current protocols and are therefore unable to deduce whether this
has impacted the observed ‘bias’. Improvements in DNA quan-
titation using more sensitive methods as mentioned and assess-
ment of DNA quality by methods such as the ProNex® DNA
QC Assay (Promega, NG1002) prior to library preparation
would enable control of DNA input quality and to triage samples
most applicable to this analytical procedure. In addition, more
recent improvements in AmpliSeq panels have resulted in the
incorporation of tag-based sequencing in which DNA is
barcoded prior to PCR, enabling the identification of duplicate
reads. The incorporation of this into the current workflow may
negate the current inaccuracies in extrapolating VAFs from this
assay.
During the validation process, the need to validate bioin-
formatic pipelines using multiple software providers became
apparent. Despite a large proportion of indels being identified
by the IonReporter™ routine analysis algorithm, we did iden-
tify issues in the routine Ion Reporter™ analysis algorithm for
the detection of some indels, a type of variant known to pres-
ent a challenge for NGS analysis [22]. Both false negatives
identified in sample sensitivity analysis were indels in KIT,
which failed to be identified by the routine Ion Reporter™
analysis workflow. Adjustment of analysis parameters, name-
ly soft-clipping (the indel was located at the end of amplicon),
enabled the successful detection of one indel by the Ion
Reporter analysis software. FASTQ files from both indels
were further analysed using NextGENe® software
(SoftGenetics®) and were successfully identified. Further in-
vestigation into indel identification demonstrated that neither
Ion Reporter™ nor NextGENe®was 100% successful in iden-
tification of five indels we ran. Further validation of this bio-
informatics workflow, i.e. IonReporter™ routine workflow
followed by NextGENe® workflow with the same detection
parameters on prospective samples, will be required to ensure
suitability of the workflow in identification of clinically appli-
cable variants. We believe that this demonstrates the
importance of robust and appropriate validation of the bioin-
formatics pipeline for clinical application and the use of mul-
tiple analysis software to ensure detection of all types of var-
iants. We also noted a number of incorrect nomenclature calls
on identified variants. We suggest that reporting of NGS-
derived results should be made by individuals experienced
in the platform, bioinformatics and clinical application of data
derived.
In conclusion, with an increasing number of clinically ac-
tionable targets requiring a variety of methodologies, an NGS
test becomes the more viable option in terms of cost, time and
availability of material. For example, within our clinical set-
ting, NSCLC samples now require a plethora of testing across
multiple modalities: ALK IHC, ALK FISH, ROS1 IHC, ROS1
FISH, PDL1 IHC and PCR for EGFR and KRAS from nor-
mally small biopsies with limited material available. NGS
enables the assessment of multiple targets using limited input
material. The challenge clinical laboratories face is in how
much future proofing is appropriate. Here, we have demon-
strated that a balance is required between testing current clin-
ically relevant targets and ensuring additional targets which do
not currently have clinical utility are a suitable trade-off for
sequencing space. It is important to take into account the cost-
ly and time-consuming validation/verification process follow-
ing assay changes when deciding on the size of panel to be
implemented into clinical practice.
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